Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited
Your view on LPCUF
Overview
What the company does, where it operates, and who runs it.
About Lee's Pharmaceutical Holdings Limited
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Siu Fong Lee
- Headquarters
- Building 20E, Sha Tin, HK
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Siu Fong Lee
- Headquarters
- Building 20E, Sha Tin, HK
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology.
It operates through Proprietary and Generic Products; and Licensed-In Products segments.
The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders.
The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis.
This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics.
The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Lee's Pharmaceutical Holdings Limited, and the rating behind it. LPCUF last traded at $0.19, 4.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Lee's Pharmaceutical Holdings Limited. Starting points for Lee's Pharmaceutical Holdings Limited: P/E 4.5, EPS $0.26, beta 0.55 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Lee's Pharmaceutical Holdings Limited. Trailing twelve-month EPS for Lee's Pharmaceutical Holdings Limited stands at $0.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Lee's Pharmaceutical Holdings Limited valued side by side against its closest peers. Lee's Pharmaceutical Holdings Limited is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Lee's Pharmaceutical Holdings Limited, and how their positions are changing. At a $112.1M market value, institutional positions materially move Lee's Pharmaceutical Holdings Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Lee's Pharmaceutical Holdings Limited executives and directors. Shares of Lee's Pharmaceutical Holdings Limited have traded between $0.19 and $0.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Lee's Pharmaceutical Holdings Limited. Lee's Pharmaceutical Holdings Limited is a $112.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Lee's Pharmaceutical Holdings Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Lee's Pharmaceutical Holdings Limited. Coverage tracks Lee's Pharmaceutical Holdings Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.